EA201400962A1 - Способ получения фармацевтической композиции на основе модафинила, полученная фармацевтическая композиция и её применение - Google Patents

Способ получения фармацевтической композиции на основе модафинила, полученная фармацевтическая композиция и её применение

Info

Publication number
EA201400962A1
EA201400962A1 EA201400962A EA201400962A EA201400962A1 EA 201400962 A1 EA201400962 A1 EA 201400962A1 EA 201400962 A EA201400962 A EA 201400962A EA 201400962 A EA201400962 A EA 201400962A EA 201400962 A1 EA201400962 A1 EA 201400962A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
modafinil
application
producing
composition based
Prior art date
Application number
EA201400962A
Other languages
English (en)
Other versions
EA024459B1 (ru
Inventor
Кристоф Лёбон
Паскаль Сюпли
Фабрис Лебёф
Дженнифер Цзун
Франц Дешан
Original Assignee
Дебрежа Э Ассосье Фарма
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дебрежа Э Ассосье Фарма filed Critical Дебрежа Э Ассосье Фарма
Publication of EA201400962A1 publication Critical patent/EA201400962A1/ru
Publication of EA024459B1 publication Critical patent/EA024459B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Closures For Containers (AREA)

Abstract

Настоящее изобретение относится к новому способу получения фармацевтической композиции на основе модафинила. Способ заключается в растворении S-модафинила в жидкости в сверхкритическом состоянии и затем после расширения этой жидкости извлечении S-модафинила путем адсорбции его на поверхности инертного носителя, представляющего собой гранулы. Данной жидкостью может быть COили другой растворитель, а носителем - безводная лактоза или маннитол. Фармацевтическую композицию применяют в случаях, когда краткосрочное повышение активности на короткий период необходимо для потребителя данной фармацевтической композиции.
EA201400962A 2012-02-28 2013-02-25 Способ получения фармацевтической композиции на основе модафинила, полученная фармацевтическая композиция и её применение EA024459B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1200580A FR2987266B1 (fr) 2012-02-28 2012-02-28 Procede d'obtention d'une composition pharmaceutique a base de modafinil, composition pharmaceutique ainsi obtenue et son application
PCT/FR2013/000051 WO2013128087A1 (fr) 2012-02-28 2013-02-25 Procédé d'obtention d'une composition pharmaceutique à base de modafinil, composition pharmaceutique ainsi obtenue et son application

Publications (2)

Publication Number Publication Date
EA201400962A1 true EA201400962A1 (ru) 2014-12-30
EA024459B1 EA024459B1 (ru) 2016-09-30

Family

ID=48083446

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201400962A EA024459B1 (ru) 2012-02-28 2013-02-25 Способ получения фармацевтической композиции на основе модафинила, полученная фармацевтическая композиция и её применение

Country Status (31)

Country Link
US (1) US9782367B2 (ru)
EP (1) EP2819654B1 (ru)
JP (1) JP6026566B2 (ru)
KR (1) KR101911989B1 (ru)
CN (1) CN104168889B (ru)
AR (1) AR090168A1 (ru)
AU (1) AU2013224830B2 (ru)
CA (1) CA2863042A1 (ru)
CL (1) CL2014002202A1 (ru)
CY (1) CY1117049T1 (ru)
DK (1) DK2819654T3 (ru)
EA (1) EA024459B1 (ru)
ES (1) ES2554794T3 (ru)
FR (1) FR2987266B1 (ru)
HR (1) HRP20151280T1 (ru)
HU (1) HUE027141T2 (ru)
IL (1) IL234008A (ru)
IN (1) IN2014DN06573A (ru)
MA (1) MA37284B1 (ru)
MX (1) MX349970B (ru)
NZ (1) NZ628007A (ru)
PH (1) PH12014501838A1 (ru)
PL (1) PL2819654T3 (ru)
PT (1) PT2819654E (ru)
RS (1) RS54435B1 (ru)
SG (1) SG11201404812QA (ru)
SI (1) SI2819654T1 (ru)
SM (1) SMT201600029B (ru)
TW (1) TWI543779B (ru)
UA (1) UA113539C2 (ru)
WO (1) WO2013128087A1 (ru)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618845A (en) 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
CN1249932A (zh) * 1999-09-29 2000-04-12 付俊昌 一种莫达芬尼及其光学对映体l及d异构体的新用途
EP1263413B1 (en) * 2000-03-09 2006-05-24 Ohio State University Research Foundation Method of preparing solid dispersions
US6919378B2 (en) 2000-10-11 2005-07-19 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
US6489363B2 (en) 2000-10-11 2002-12-03 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
US7297346B2 (en) 2001-05-25 2007-11-20 Cephalon Inc. Pharmaceutical formulations of modafinil
US20040048931A1 (en) 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
US20040121003A1 (en) 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US20060024370A1 (en) * 2004-07-29 2006-02-02 Cephalon France Modafinil oral lyophilizate
GB0523653D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
PL1909973T3 (pl) * 2005-07-15 2019-01-31 Micell Technologies, Inc. Polimerowe powłoki zawierające proszek leku o kontrolowanej morfologii
WO2007013962A2 (en) * 2005-07-21 2007-02-01 Neurohealing Pharmaceuticals, Inc. Rapid onset and short term modafinil compositions and methods of use thereof
MX2009000391A (es) * 2006-07-12 2009-06-30 Elan Pharma Int Ltd Formulación de modafinilo en forma de nano-partículas.
US8173169B2 (en) * 2007-07-11 2012-05-08 Hikma Pharmaceuticals Formulation and process for the preparation of modafinil
FR2943543B1 (fr) 2009-03-31 2013-02-08 Separex Sa Procede de preparation de compositions pharmaceutiques comprenant des particules fines de substance active.
KR100924236B1 (ko) * 2009-06-23 2009-10-29 충남대학교산학협력단 균일한 입도분포를 가지는 초미세입자의 신규한 제조방법 및 장치

Also Published As

Publication number Publication date
IN2014DN06573A (ru) 2015-06-26
EP2819654B1 (fr) 2015-09-09
KR101911989B1 (ko) 2018-10-25
ES2554794T3 (es) 2015-12-23
MA20150242A2 (fr) 2015-07-31
AU2013224830B2 (en) 2017-02-02
FR2987266B1 (fr) 2014-12-19
DK2819654T3 (en) 2015-12-21
CN104168889B (zh) 2016-10-26
UA113539C2 (xx) 2017-02-10
MA37284B1 (fr) 2016-06-30
CY1117049T1 (el) 2017-04-05
IL234008A (en) 2017-02-28
AU2013224830A1 (en) 2014-08-21
US9782367B2 (en) 2017-10-10
EP2819654A1 (fr) 2015-01-07
JP6026566B2 (ja) 2016-11-16
MX2014010236A (es) 2015-04-09
JP2015508804A (ja) 2015-03-23
SI2819654T1 (sl) 2015-12-31
PT2819654E (pt) 2015-12-21
HK1198931A1 (en) 2015-06-19
EA024459B1 (ru) 2016-09-30
WO2013128087A1 (fr) 2013-09-06
US20150105470A1 (en) 2015-04-16
CA2863042A1 (fr) 2013-09-06
IL234008A0 (en) 2014-09-30
FR2987266A1 (fr) 2013-08-30
SMT201600029B (it) 2016-02-25
RS54435B1 (sr) 2016-06-30
PH12014501838B1 (en) 2014-11-10
PL2819654T3 (pl) 2016-02-29
SG11201404812QA (en) 2014-10-30
KR20140129035A (ko) 2014-11-06
MX349970B (es) 2017-08-23
HRP20151280T1 (hr) 2016-01-01
NZ628007A (en) 2015-07-31
CN104168889A (zh) 2014-11-26
PH12014501838A1 (en) 2014-11-10
TWI543779B (zh) 2016-08-01
TW201340995A (zh) 2013-10-16
AR090168A1 (es) 2014-10-22
CL2014002202A1 (es) 2015-03-13
HUE027141T2 (hu) 2016-08-29

Similar Documents

Publication Publication Date Title
CL2014003121A1 (es) Formulacion liquida que comprende propilenglicol y un inodilatador, un inhibidor de la enzima convertidora de angiotensina o una combinacion de ambos; proceso para prepararla; kit; y metodo de tratamiento de una enfermedad cardiaca y/o hipertension.
CO2018003828A2 (es) Ácido (s) -3-amino-4- (difluorometilenil) ciclopent-1-eno-1-carboxílico, y compuestos relacionados como inactivadores de gaba aminotransferasa
CL2015000392A1 (es) Método para la eliminación de sulfato, calcio y/u otros metales solubles de aguas residuales
EP3078744A4 (en) Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
WO2012159051A3 (en) Chemically modified graphene
EA201391332A1 (ru) Лиганды опиоидных рецепторов и способы их применения и получения
WO2014014835A8 (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
GB2515226A (en) Gyroscopes based on nitrogen-vacancy centers in diamond
EA201691374A1 (ru) Инсулин длительного действия и его применение
BR112012029213A2 (pt) processo para separar furfural a partir de uma fase aquosa líquida, e, uso de um composto de hidrocarboneto aromático
EA201690639A1 (ru) Смеси из ионной жидкости и растворителя для удаления сероводорода
WO2013066369A3 (en) Methods for detecting graft-versus-host disease
WO2015056237A3 (en) Purification of proteins
EA201400853A1 (ru) Способы извлечения и/или удаления реагентов из пористой среды
UA111979C2 (uk) Спосіб екстракції лютеїну з природних матеріалів
EA201890002A1 (ru) Положительные аллостерические модуляторы мускаринового рецептора м2
LT3151853T (lt) Glutamo rūgšties dekarboksilazė (gad), skirta panaudoti autoimuninės ligos gydyme
EA201590698A1 (ru) Жидкофазные способы получения макроциклических депсипептидов и новые промежуточные соединения
EA201791312A1 (ru) Способы мечения библиотек, кодируемых днк
HK1247663A1 (zh) 药用级斑蝥素的定量和制备
DK2880945T3 (da) Signalering til epdcch-ressourcetiilknytning som støtte til comp
NZ722412A (en) Methods of preparing a hydrochloride salt of (1r,2r,5r)-5-amino-2-methylcyclohexanol
BR112015003122A2 (pt) poli(2-ácido hidroxialcanoico ) e método de sua fabricação
IN2014MU03425A (ru)
WO2013024398A3 (en) Improved method for quantitative determination of linezolid

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ RU